SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada.

Bitfarms Ltd.

Bitfarms ($BITF) is trending as discussions revolve around its strategic shift toward AI and high-performance computing, alongside a recently announced offering. The community is weighing the potential impact of this move, with some viewing it as a positive step for long-term growth, while others express concerns about potential dilution. Investors are actively debating the implications of the offering and the company's future prospects in the evolving landscape of AI and cryptocurrency.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is trending due to positive topline results from Phase 3 trials of ulixacaltamide HCl for essential tremor, sparking significant pre-market gains and heavy trading volume. The community is focused on the high institutional ownership potentially leading to a short squeeze, with some speculating on price targets. This movement occurs within the context of the essential tremor treatment space, where there is a large unmet need for effective therapies.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to a lawsuit from Singapore's GIC alleging inflated revenue figures, sparking debate about its impact. The community is divided, with some viewing it as a buying opportunity amidst recycled headlines and others expressing concern. Discussions also include delivery numbers, battery swap technology, and the broader context of Chinese EV competition.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending as analysts update their ratings, citing a clear path to growth and potential investor sentiment improvement, especially with the company's AI integrations. Community discussions revolve around potential revival of the AI software/enterprise trade and possible short-term trading opportunities. The stock also garnered attention following Salesforce and Google's deepened partnership with Gemini integration, further emphasizing the company's focus on AI.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending after reporting strong Q3 earnings, driven by surging AI chip demand, and raising its 2025 revenue growth outlook. Community members are discussing the company's impressive profit increase and potential for further gains, while also noting geopolitical risks. Some analysts are raising price targets, citing TSMC's key role in the AI boom and strong guidance.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach record highs, sparking debate about a potential bubble. While some community members foresee a continued surge driven by economic uncertainty and central bank buying, others anticipate a sharp correction, citing overbought conditions. Discussions revolve around shorting opportunities versus long-term bullish sentiment amidst global economic concerns.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as community members debate its valuation and potential for a short squeeze, with some citing insider selling as a cause for concern. Discussions include potential catalysts for movement, such as earnings and possible offerings, amid speculation about the future of quantum computing stocks. Bears and bulls continue to clash over the stock's direction and long-term potential.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

ABAT is trending due to the termination of a DOE grant for its lithium hydroxide project, leading to a significant price drop and high trading volume. While the company is appealing the decision and states the project will continue unchanged, the community is debating the impact of the lost funding and potential need for alternative financing. Some investors view the dip as a buying opportunity, citing the company's long-term potential and strategic importance in the domestic battery technology sector.

Veritone, Inc. engages in the provision of artificial intelligence (AI) computing solutions to media and entertainment, government, and legal and compliance industries. It operates through the following segments: Advertising, aiWARE SaaS Solutions, and aiWARE Content Licensing and Media Services. The Advertising segment places advertisements for clients, primarily with radio broadcasters, podcasters and digital media producers. The aiWARE SaaS Solutions segment offers solutions through a combination of its direct sales force and indirect channel partners, such as value-added resellers (VARs), distributors, system integrators, managed services providers, and referral partners. The aiWARE Content Licensing and Media Services segment sells and markets activities relating to its digital content licensing services business through its direct sales force. The company was founded by Chad Edward Steelberg and Ryan S. Steelberg on June 13, 2014 and is headquartered in Denver, CO.

Veritone Inc

Veritone (VERI) is trending due to a registered direct offering of $75 million, leading to community discussion about dilution and management's timing. While some investors express concerns about the offering's impact on share value, others view it as a necessary step for growth and debt repayment, emphasizing the company's long-term potential in the AI sector. Community members are actively debating whether this dip presents a buying opportunity or signals further downside.

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

MVST is trending as investors discuss its valuation relative to peers and potential catalysts like earnings and expansion plans. Community members are pointing to potential short squeezes and institutional buying, while also debating the company's ties to China. Overall, the discussion revolves around whether the stock is undervalued and poised for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Praxis Precision Medicines, Inc. (PRAX) announced on Thursday that patients with essential tremor treated with Ulixacaltamide in a late-stage study showed improvement in functional independence.A 4.3 point mean improvement in the Modified Activities of Daily Living 11 (mADL11) score was observed at week 8 in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1">said</a>. The score is used to assess a person's functional independence and evaluate a person’s ability to do day-to-day activities. Furthermore, the effect was sustained from week 2 throughout the 12-week dosing period, it added.Essential Tremor is the most common movement disorder, affecting roughly seven million people in the U.S. alone, according to Praxis. It is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs.Praxis now plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026. Shares of the company rallied 76% in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory, while message volume increased from ‘low’ to ‘extremely high’ levels.The company said that Ulixacaltamide was generally well-tolerated over 12 weeks of treatment, and no deaths or drug-related serious adverse events were recorded. However, discontinuations in the study were 35.6% in patients who received Ulixacaltamide as compared to 5.6% in patients who received placebo, and most discontinuations were primarily due to treatment-emergent adverse events, it said.The company also conducted another late-stage trial where patients showed superior maintenance of effect while on Ulixacaltamide versus placebo after blinded exposure for 8 weeks with Ulixacaltamide.PRAX stock is down by 25% this year and by about 23% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.

Equity

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.


Hillenbrand (HI) announced on Wednesday that it has entered into a definitive agreement to be acquired by an affiliate of Lone Star Funds in an all-cash transaction valuing the company at $3.8 billion.Shares of Hillenbrand jumped nearly 19% in premarket trading after the company said it would be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price of $23.43 on August 12. The transaction is expected to close by the end of the first quarter of calendar year 2026.Retail sentiment on <a href="https://stocktwits.com/symbol/HI">Hillenbrand</a> improved to ‘neutral’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits.&nbsp;“The Board carefully reviewed a range of potential strategic alternatives, including interest from a number of parties, and determined that this transaction is in the best interest of Hillenbrand and its shareholders,” said Helen Cornell, Chairperson of the Board of Directors.Hillenbrand said that once the deal is closed, it will become a privately held company, and the company’s shares will no longer trade on the New York Stock Exchange. Shares of the company traded nearly 3% higher in Wednesday’s pre-market session.The company said during its fourth-quarter results that it would not be issuing financial guidance for fiscal year 2026.Hillenbrand is known for providing processing equipment and solutions to customers around the world through its Advanced Process Solutions and Molding Technology Solutions segments.&nbsp;Shares of Hillenbrand have declined nearly 14% this year and have fallen 6% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-dollar-tree-stock-rising-today/ch6nw5IR3NW">Why Is Dollar Tree Stock Rising Today?</a>

Hillenbrand To Go Private In Nearly $4B Deal With Affiliate Of Lone Star Funds

The company will be bought for $32.00 per share, which represents a premium of approximately 37% over Hillenbrand's unaffected closing share price on August 12.

Polaris (PII) stock witnessed price target hikes on Tuesday after the specialty vehicle manufacturer announced a deal to separate its Indian bike operations from its portfolio and into a standalone business.BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 while keeping a ‘Neutral’ rating on the shares after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood, as per TheFly.Roth Capital analyst Scott Stember, meanwhile, raised the firm's price target on the stock to $54 from $41 and kept a ‘Neutral’ rating on the shares. While BofA’s new price target implies a potential upside of about 14% from the stock’s closing price on Monday, Roth Capital’s new target suggests a potential downside of about 12%.Shares of Polaris traded 13% higher on Tuesday at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PII">PII stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_1_23_30_PM_png_136d55f245.webp" alt="PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="587" height="62"><figcaption>PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s move as a good decision.<stembedurl>https://stocktwits.com/Lying___Dandy/message/632206305</stembedurl>Polaris did not disclose the size of the deal with Carolwood on Monday but <a href="https://stocktwits.com/news-articles/markets/equity/polaris-stock-jumps-on-deal-to-sell-indian-bikes-brand/ch6mQ4ER3l1">said</a> the divestiture would boost Polaris's annualized adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by about $50 million and annualized adjusted earnings by $1 a share. The closing of the transaction is expected in the first quarter of 2026.CEO Mike Speetzen said the sale would enable Polaris to focus on the parts of its business that have the most growth potential. However, the company said it would continue to maintain a small equity position in the Indian Motorcycle business after the closing of the transaction.Polaris also said on Monday that it expects third-quarter sales to be at the high end of its previously issued guidance range of $1.6 billion to $1.8 billion. The company now anticipates third-quarter adjusted earnings per share to be in the range of $0.31 to $0.41, higher than its original expectations.Speetzen said the higher expectations are driven by higher-than-expected shipments, strong cost management, and ongoing progress within operational efficiency initiatives.PII stock is up by 20% this year and down by about 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bikes from Indian Motorcycle, owned by Polaris, at the Minneapolis Convention Center in 2014. (Photo By Marlin Levison/Star Tribune via Getty Images)

Polaris Stock Gets Price Target Hikes After Selling Indian Bike Business To Private Equity Firm

BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood.

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah Capital, called for the sale of the company, citing persistent underperformance.Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.shahcapital.com/shah-capital-calls-for-sale-of-novavax/">said</a> in a letter to the Novavax board of directors that since March 2023, its concerns have accelerated with “Nuvoxovid’s rollout slipups including this fall, timid/ineffective marketing, extremely poor capital market actions, and tremendous lack of accountability.”“Novavax’s IP and scientific capabilities will have far greater upside potential in the hands of large capable pharma entity,” Shah Capital said, while recommending an immediate formal strategic review for the sale of the company.The investor recapped several alleged missteps that have damaged the company, including critical marketing slips resulting in a small 2% Covid vaccine market share in the 2024 season for Novavax’s protein-based Nuvaxovid vaccine.Shah Capital also expressed surprise at Nuvaxovid’s market share, noting that the increasing criticism for mRNA vaccines made by Novavax’s peers should benefit Novavax’s protein-based vaccine.“With more states becoming increasingly averse to mRNA vaccines including Florida, Texas, Minnesota, Idaho, Iowa, Montana, South Carolina, Tennessee &amp; Kentucky; some of which are trying to ban mRNA altogether, we find it inconceivable as to how management has been unsuccessful gaining meaningful share given the tens of millions of senior citizens/high risk/immunocompromised individuals in just those 9 states alone. Sales are miserable for the third consecutive year,” it said.The investor also noted that awareness regarding Nuvaxovid continues to be “alarmingly low.” Shah further alleged that the “execution failure and ineffective leadership” have taken their toll on investor confidence and trust.Last year, Shah Capital waged a proxy campaign against the re-election of some directors on the company board at Novavax’s 2024 Annual Meeting, but withdrew it after the company struck a licensing agreement with Sanofi.Sanofi is Novavax’s biggest partner. In the second quarter (Q2), the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> is up by 7% this year but down by about 32% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-appoints-ceo-charlie-scharf-as-chairman-after-q3-earnings-beat-estimates/ch6mVM6R3mE">Wells Fargo Appoints CEO Charlie Scharf As Chairman After Q3 Earnings Beat Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity

Shah Capital currently owns 11.8 million shares or 7.2% of Novavax.

SELLAS Life Sciences Group (SLS) announced on Monday that preclinical data support its SLS009 as a monotherapy or in combination with Venetoclax for treating a rare and highly aggressive form of mature T-cell leukemia.The biopharmaceutical company said that data supporting the drug in T-cell prolymphocytic leukemia will be presented at the European Society for Medical Oncology Congress 2025, being held October 17 to October 21, in Berlin, Germany. T-PLL or T-cell prolymphocytic leukemia is a rare, aggressive type of mature T-cell leukemia that primarily affects older adults, characterized by the rapid growth of cancerous T-cells.SELLAS <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-to-Present-In-Vivo-Preclinical-Data-Demonstrating-Statistically-Significant-Survival-Benefit-of-SLS009-in-T-Cell-Prolymphocytic-Leukemia-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2025/default.aspx">said</a> that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference. The combination regimen, which prolonged overall survival to 7.9 weeks, was also well tolerated in the study, the company said.Chief Development Officer at SELLAS, Dragan Cicic, said that the results from the study are “highly encouraging” and noted that T-PLL has minimal treatment options.SLS shares traded 5% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLS">SLS stock</a> remained in the ‘bullish’ territory, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:622/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_11_30_56_AM_png_b0f4827381.webp" alt="SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="622" height="61"><figcaption>SLS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user wondered why the stock didn’t rally further on the news.<stembedurl>https://stocktwits.com/SunnySeed/message/632108231</stembedurl>SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.SLS stock has nearly doubled this year and is up about 60% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/whats-driving-the-rally-in-ndra-stock-today/ch6Sk9VR3kY">What’s Driving The Rally In NDRA Stock Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS said that in a study model, SLS009 monotherapy and the combination prolonged overall survival compared to Venetoclax alone, with a statistically significant difference.

Planet Labs (PL) is reportedly set to deploy a new constellation of Earth observation satellites, which are designed to deliver high-resolution, AI-enhanced imagery within an hour.According to a Bloomberg News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-08/planet-labs-to-launch-satellites-promising-images-in-an-hour?srnd=homepage-americas">report</a>, the newly introduced monitors, known as Owl, will bolster Planet Labs’ current fleet of approximately 150 imagery spacecraft in orbit. The report added that these systems are designed to monitor changes, from natural disaster impacts to the movement of vessels and aircraft.Planet Labs is looking to build and launch nearly 40 Owl satellites in the coming few years, with the initial test launch for these slated towards late 2026, Chief Executive Officer Will Marshall told Bloomberg in an interview.“Looking at the nature of modern war situations from Israel in the Middle East to Ukraine, people have seen that satellites and drones are critical to information advantage, which in turn is critical to their security,” Marshall said, according to the report.Retail sentiment on <a href="https://stocktwits.com/symbol/PL">Planet Labs</a> remained unchanged in the ‘bullish’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to data from Stocktwits. Shares of the company were up 1% in early trading.The report added that Nvidia Corp’s (NVDA) chips will be used in these Owl satellites and will help in using artificial intelligence to search and identify events on Earth quickly. Bloomberg noted that the company said this was to ensure that customers can make real-time decisions in case of disaster relief, intelligence gathering and military responses.Shares of Planet Labs have gained 638% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="http://stocktwits.com/news-articles/markets/equity/best-buy-shares-jump-2-as-jefferies-sees-advertising-boosting-margins/ch6EZaGR3in">Best Buy Shares Jump 2% As Jefferies Sees Advertising Boosting Margins</a>

In this photo illustration, a smartphone held in a hand shows the logo of Planet Labs PBC

Planet Labs To Provide Images Within An Hour Using New Earth Observation Satellites: Report

According to a Bloomberg News report, the newly introduced monitors, known as Owl, will bolster Planet Labs’ current fleet of approximately 150 imagery spacecraft in orbit.

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the treatment of Friedreich's ataxia (FA) cardiomyopathy, scheduled to begin in the first half of 2026, pending finalization of the study protocol.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-progress-fda-discussions">data</a> from the planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy, the company stated after discussions with the agency.Lexeo will submit enhanced manufacturing comparability data and meet an additional nonclinical requirement before the initiation of the planned pivotal study to enable pooling, the company added.Lexeo is continuing to engage with the agency regarding the protocol of the pivotal study, it stated, adding that it believes this regulatory feedback has the potential to reduce the size and duration of the planned pivotal study. The company is also optimistic that the feedback may accelerate the overall timeline to an application submission.Updated interim clinical data from both ongoing Phase I/II studies of LX2006 show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich’s ataxia, the company said.FA cardiomyopathy is the leading cause of death in individuals with Friedreich’s ataxia (FA), a rare, inherited neurodegenerative disorder causing progressive damage to the nervous system, leading to impaired balance, muscle coordination, and sensory loss, often beginning in childhood. It is estimated to affect approximately 5,000 people in the U.S.Shares of the company rallied 24% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LXEO">LXEO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1368/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_9_19_18_AM_png_3d23b7c692.webp" alt="LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1368" height="120"><figcaption>LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>LXEO stock has risen 22% this year and but fallen by approximately 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-slashes-workforce-at-its-us-wegovy-manufacturing-plant/ch6PBqJR3WD">Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

The company stated that data from a planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy. 

Plug Power (PLUG) announced on Tuesday that it has appointed insider Jose Luis Crespo as its new Chief Executive Officer, succeeding long-time head Andy Marsh.&nbsp; Shares of the company fell over 1% at the opening bell.The company stated that Marsh will continue to serve as CEO during the transition period and has been appointed executive chair of the board, a position he will retain after March 2, 2026. In conjunction, George McNamee has been named Lead Director, and the company said that both Board appointments are effective Oct. 10, 2025.The appointment of Crespo is to be effective as of the date the company files its annual report for the year ended Dec. 31, 2025. This is expected in March 2026.&nbsp;“My focus will be on execution, profitability, and customer success, ensuring that Plug continues to convert its technology leadership into sustainable growth,” Crespo said.Retail sentiment on <a href="https://stocktwits.com/symbol/PLUG">Plug Power</a> improved to ‘extremely bullish’ from ‘bullish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Crespo joined&nbsp;Plug Power in 2014 and most recently served as Chief Revenue Officer. The company stated that, in his roles with the firm for more than a decade, Crespo has played a pivotal role in Plug’s growth, serving as the primary architect of a sales funnel that has generated over $8 billion in transformational opportunities.&nbsp;Plug also said that Crespo has been instrumental in strengthening relationships with key customers such as Amazon, Walmart, and Home Depot, while driving hydrogen adoption programs.Plug Power stock has rallied 76% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/applovin-rises-5-premarket-after-citigroup-recommends-buying-the-stock/ch6PfUIR3hP">AppLovin Rises 5% Premarket After Citigroup Recommends Buying The Stock Amid SEC Investigation Concerns</a>

Plug Power Names Insider Jose Luis Crespo As New CEO

Plug Power said that current CEO Andy Marsh will continue to serve in his position during the transition period and has been appointed executive chair of the board, a position he will retain following March 2, 2026. 

A White House official reportedly stated on Monday that the Trump administration was not evaluating a deal to acquire a stake in Critical Metals Corp (CRML) following a Reuters report that the government was considering such a move, which sparked a surge in the rare earths company's stock.Shares of Critical Metals still traded over 46% higher in afternoon trading on Monday. According to a Bloomberg News report, a White House official stated that the administration was in regular contact with the private sector and had received hundreds of deal proposals involving equity stakes.The report added that no active discussions were underway regarding a deal with Critical Metals, which is involved in Greenland’s largest rare earths project. The Reuters report noted that the U.S. was aiming to secure access to Greenland’s Tanbreez project, which Critical Metals acquired last year for $5 million in cash and $211 million in stock.Retail sentiment on <a href="https://stocktwits.com/symbol/CRML">Critical Metals</a> remained unchanged in the ‘extremely bullish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Bloomberg reported that U.S. President Donald Trump has unveiled several agreements in recent months, in which companies have traded equity stakes in return for access to government loans and subsidies. The report added that last month, the U.S. took a 5% stake in Lithium Americas and announced the Vancouver-based company could draw on a previously agreed-upon $2.23 billion loan. In August, Intel Corp announced that the U.S. government would take a 9.9% stake in the firm for $8.9 billion.Critical Metal shares have gained nearly 75% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dollar-tree-shares-dip-after-bernstein-cuts-price-target/ch6RJjIR3g8">Dollar Tree Shares Dip After Bernstein Cuts Price Target On EBIT Performance</a>

U.S. President Donald Trump announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. (Photo by Win McNamee/Getty Images)

White House Reportedly Denies Plans To Acquire Stake In Critical Metals

According to a Bloomberg News report, there were no active discussions underway regarding a deal with Critical Metals, which is involved in Greenland’s largest rare earths project.

Leerink lowered its price target on Rocket Pharmaceuticals (RCKT) to $7 from $9 on Friday, following the company's announcement that it has voluntarily withdrawn its application for the approval of Fanskya to the U.S. Food and Drug Administration for the treatment of Fanconi Anemia.The analyst kept a ‘Market Perform’ rating on the shares, according to TheFly. The new price target, however, implies a potential upside of approximately 118% from the stock’s closing price on Thursday.Rocket Pharma <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001281895/000114036125037163/ef20056613_8k.htm">stated</a> in a filing with the Securities and Exchange Commission that the decision to withdraw the application for the gene therapy follows its decision to focus its resources on programs with the clearest regulatory and commercial pathways. The decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya or RP-L102, the company said.“Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable,” it added.The company ceased internal investment in Fanskya in July 2025 and withdrew its application with the European Medicines Agency (EMA) as part of a pipeline prioritization and corporate reorganization plan. The company had then warned that FDA approval of Fanskya is no longer expected in 2026.The therapy was tested in the treatment of Fanconi Anemia, a rare, inherited disorder characterized by a failure of the bone marrow to produce enough blood cells, leading to symptoms like fatigue, bleeding, and infections, as well as physical abnormalities and a significantly increased risk of certain cancers. &nbsp;The company said on Friday that it will consider external partnership opportunities to advance Fanskya in the future. “Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program,” it said.<a href="https://stocktwits.com/symbol/RCKT">Shares of RCKT</a> fell 2% at the time of writing. On Stocktwits, retail sentiment around RCKT remained within the ‘bearish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_57_15_PM_png_0ff4527f20.webp" alt="RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure> In August, Rocket Pharma <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> that the FDA had lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.RCKT stock is down by 75% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-to-schizophrenia-drug/chCuoM8R3QK">Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sculpture depicting a DNA strand in front of the Lawrence Hall of Science at UC Berkeley on Saturday, March 31, 2018. (Photo By Paul Chinn/The San Francisco Chronicle via Getty Images)

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 

iShares Trust - iShares Russell 2000 BuyWrite ETF

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$40.84
Prev Close	$40.83
Open	$40.92
Dividend Yield	N/A
50-Day Moving Average	$40.14
Beta	N/A
Avg. Volume	7,567.67
PE Ratio	N/A

52-Week High	$49.18
52-Week Low	$34.29
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWMW News

IWMWiShares Russell 2000 BuyWrite ETF